Licensing

SANTA ROSA, Calif. Former MinuteClinic regional medical director Francisco Trilla has joined Santa Rosa Community Health Centers, according to local news reports.

Trilla will serve as the new chief medical officer of Santa Rosa Community Health Centers, overseeing clinical programs at all of its eight facilities with "an emphasis on access and quality," according to reports.

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

MINNEAPOLIS Target is looking to open eight new Target Clinic locations in Chicago and Palm Beach, Fla., in September.

Target currently has 28 clinics in Minnesota and Maryland, according to the website. The healthcare services in Minnesota and Maryland are provided by Target Clinic Medical Associates, an unaffiliated corporation not owned or operated by Target Corp. Fees for most services range from $59 to $69.

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.